Our client was looking to assess treatment centers in the US to identify the most relevant hospitals for delivering novel gene therapies that are indicated for Heart Failure.
The goal was to better understand the treatment centers readiness, capacity, and timelines for onboarding a new heart failure gene therapy.
10EQS supported the Client with conducting double-blinded interviews with a cross-section of stakeholders, including Heart Failure Specialists, Interventional Cardiologists, and Surgeons to assess clinical readiness, infrastructure, and onboarding feasibility. Experts were rigorously screened for relevant specialty, experience, and involvement in advanced heart failure treatment and related procedures.
10EQS determined treatment centers demonstrating strong clinical alignment and operational preparedness, along with detailed insights on activation timelines, staffing, and infrastructure capabilities. The findings enabled the client to prioritize strategic sites for partnership and inform their potential launch strategy.
Get in touch with us and we will get back to you immediately.
10EQS needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy.
%2C%20Color%3DNegative.svg){kind=small}
